Blueprint Medicines(US:BPMC)2023-10-26 19:35AYVAKIT Performance - AYVAKIT's Q3 2023 revenue increased by 90% year-over-year[11, 13] - Approximately 800 patients were on AYVAKIT therapy in Q3 2023[11, 32] - 95% of U S lives are now covered for AYVAKIT's broad ISM label[25, 26] - The average time to fill AYVAKIT prescriptions is approximately 10 days[28] - In Q3 2023, 70% of new SM patient starts were prescribed a 25mg dose of AYVAKIT[34, 40] Financial Overview - Total revenue for Q3 2023 was $56 6 million, compared to $65 9 million in Q3 2022[43] - Net product sales for Q3 2023 were $54 2 million, a significant increase from $28 6 million in Q3 2022[43] - Research & Development expenses for Q3 2023 were $110 3 million[43] - The company had $827 2 million in cash, cash equivalents, and investments as of September 30, 2023[43] Strategic Focus - The company aims to penetrate a broader range of ISM patients, increase market growth through increased diagnosis, and expand geographically beyond the U S [37]